TITLE

GENERICS INCURSION CAUSES A CYTOTOXIC MARKET DECLINE

PUB. DATE
January 2009
SOURCE
Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article relates the prediction of independent market analyst Datamonitor that influx of generic drugs will lead to a decline in total cytotoxic market value in 2013. Cytotoxic therapies, which according to the article, are the second largest class of cancer therapeutics, involve the use of drugs that are toxic to all cells. Information on the sales of the 25 cytotoxic therapy cancer brands in 2007 is discussed in detail. Also noted is a brief background on Datamonitor.
ACCESSION #
35859762

 

Related Articles

  • Australia's top 20 cancer drugs to reach sales of $1 billion by 2018.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p18 

    The article presents a forecast by Datamonitor Inc. that the top 20 cancer drugs in Australia will reach sales of 1 billion U.S. dollars by 2018. It states that cancer therapy brands are divided to three main drug classes including molecular targeted therapies, cytotoxic therapies and...

  • Anticancer Drugs. Polastro, Enrico T.; Tulcinsky, Sonia // Contract Pharma;2009, Vol. 11 Issue 8, p86 

    The article discusses the impact of anticancer drugs on the pharmaceutical industry. It notes that around 50 billion U.S. dollars is accounted for global sales of anticancer drugs which corresponds to 7% of total pharmaceutical demand and is predicted to grow 12% per annum until 2014. It cites...

  • Avastin Sales is Lower Than Expected.  // Bioworld Week;4/21/2008, Vol. 16 Issue 16, p2 

    The article reports on the lower-than-expected sales of Avastin drug from Genentech Inc. despite of an 8% increase in product sales in 2007. It is stated that the report has caused investors to worry that the drug's approval in breast cancer might not correlate to an immediate jump in sales. The...

  • Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Glaspy, J.A.; Jadeja, J.S.; Justice, G.; Kessler, J.; Richards, D.; Schwartzberg, L.; Tchekmedyian, N.S.; Armstrong, S.; O'Byrne, J.; Rossi, G.; Colowick, A.B. // British Journal of Cancer;7/29/2002, Vol. 87 Issue 3, p268 

    Assesses the safety of darbepoetin alfa in patients receiving cancer chemotherapy. Feasibility of administering darbopoetin every versus every two weeks; Drug dosage; Dose-response relationships.

  • Preface [Hot topic: Anti-Cancer Drugs (Executive Editor : Elke Bergmann-Leitner)]. Bergmann-Leitner, Elke // Current Pharmaceutical Design;Oct2003, Vol. 9 Issue 25, p1 

    Despite decades of intensive research there have only been a limited number of small success stories in the area of cancer treatment. This issue of Current Pharmaceutical Design features several novel approaches in the development of anti-cancer treatments. Cancer, being one of the leading...

  • Combinations of Targeted Therapies Take Aim at Multiple Pathways. Goldman, Bruce // JNCI: Journal of the National Cancer Institute;11/19/2003, Vol. 95 Issue 22, p1656 

    Part I. Focuses on the use of novel targeted drugs in the treatment of cancer. Differences of the drugs with existing products; Targeted drugs from various companies; Mechanism of action; Combination trials of targeted therapies.

  • Demand Grows for Early Access to Promising Cancer Drugs. Baldwin, Joyce // JNCI: Journal of the National Cancer Institute;11/20/2002, Vol. 94 Issue 22, p1668 

    Discusses the influence of expanded access programs in cancer patients' access to investigational drugs in the U.S. Patients' receipt of investigational drugs earlier than phase III of the clinical trial process; Patient advocacy groups' role in the growth of expanded access programs; Factors...

  • CME Questions.  // Clinical Oncology Alert;May2007, Vol. 23 Issue 5, p39 

    A quiz concerning the drugs for the treatment of cancer is presented.

  • Vandetanib Tablets (Zactima). Elliott, William T.; Chan, James // Internal Medicine Alert;5/15/2011, Vol. 33 Issue 9, p69 

    The article offers information on the effectiveness of Vandetanib tablets, marketed under the brand name Zactima from the company AstraZeneca, in treating patients with medullary thyroid cancer (MTC).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics